Molecure S.A. (MOC.WA)

PLN 10.0

(-1.96%)

EBITDA Summary of Molecure S.A.

Molecure S.A.'s latest annual EBITDA in 2023 was -25.5 Million PLN , down -17.8% from previous year.
Molecure S.A.'s latest quarterly EBITDA in 2024 Q3 was -5.24 Million PLN , up 19.53% from previous quarter.
Molecure S.A. reported an annual EBITDA of -31.84 Million PLN in 2022, down -4.53% from previous year.
Molecure S.A. reported an annual EBITDA of -13.33 Million PLN in 2021, down -118.04% from previous year.
Molecure S.A. reported a quarterly EBITDA of -6.55 Million PLN for 2024 Q2, down -6.83% from previous quarter.
Molecure S.A. reported a quarterly EBITDA of -6.34 Million PLN for 2024 Q1, up 2.28% from previous quarter.

Annual EBITDA Chart of Molecure S.A. (2023 - 2015)

Historical Annual EBITDA of Molecure S.A. (2023 - 2015)

Year	EBITDA	EBITDA Growth
2023	-25.5 Million PLN	-17.8%
2022	-31.84 Million PLN	-4.53%
2021	-13.33 Million PLN	-118.04%
2020	73.87 Million PLN	2021.79%
2019	-3.91 Million PLN	11.64%
2018	-4.38 Million PLN	-88.56%
2017	-2.3 Million PLN	0.54%
2016	-2.31 Million PLN	-385.93%
2015	-477.47 Thousand PLN	0.0%

Year	EBITDA	EBITDA Growth
2024 Q3	-5.24 Million PLN	19.53%
2024 Q2	-6.55 Million PLN	-6.83%
2024 Q1	-6.34 Million PLN	2.28%
2023 Q2	-3.68 Million PLN	-31.37%
2023 FY	- PLN	-17.8%
2023 Q3	-3.59 Million PLN	2.21%
2023 Q4	-6.24 Million PLN	-73.45%
2023 Q1	-2.8 Million PLN	49.81%
2022 Q2	-3.4 Million PLN	-18.15%
2022 Q4	-5.58 Million PLN	-195.03%
2022 FY	- PLN	-4.53%
2022 Q1	-2.88 Million PLN	56.8%
2022 Q3	-1.89 Million PLN	44.5%
2021 Q4	-6.68 Million PLN	-186.22%
2021 FY	- PLN	-118.04%
2021 Q3	-2.33 Million PLN	3.73%
2021 Q2	-2.42 Million PLN	-28.12%
2021 Q1	-1.89 Million PLN	-102.5%
2020 Q2	-424.89 Thousand PLN	46.13%
2020 Q3	-687.94 Thousand PLN	-61.91%
2020 Q4	75.8 Million PLN	11118.35%
2020 FY	- PLN	2021.79%
2020 Q1	-788.77 Thousand PLN	33.46%
2019 Q1	-1.17 Million PLN	34.08%
2019 Q4	-1.18 Million PLN	-52.13%
2019 Q3	-779.22 Thousand PLN	-13.74%
2019 Q2	-685.09 Thousand PLN	41.65%
2019 FY	- PLN	11.64%
2018 Q4	-1.78 Million PLN	-89.29%
2018 Q2	-1.31 Million PLN	-138.95%
2018 Q1	-552.08 Thousand PLN	64.38%
2018 FY	- PLN	-88.56%
2018 Q3	-940.94 Thousand PLN	28.67%
2017 Q1	-451.37 Thousand PLN	74.17%
2017 Q4	-1.54 Million PLN	-2981.87%
2017 FY	- PLN	0.54%
2017 Q3	-50.28 Thousand PLN	79.79%
2017 Q2	-248.82 Thousand PLN	44.87%
2016 Q3	-40.24 Thousand PLN	87.68%
2016 Q4	-1.74 Million PLN	-4242.01%
2016 FY	- PLN	-385.93%
2016 Q1	-326.61 Thousand PLN	0.0%
2016 Q2	-326.61 Thousand PLN	0.0%
2015 FY	- PLN	0.0%

Peer EBITDA Comparison of Molecure S.A.

Name	EBITDA	EBITDA Difference
Bioceltix S.A.	-13.22 Million PLN	-92.87%
BIOTON S.A.	43.89 Million PLN	158.104%
Captor Therapeutics Spolka Akcyjna	-64.76 Million PLN	60.617%
Mabion S.A.	58.31 Million PLN	143.739%
NanoGroup S.A.	-7.87 Million PLN	-224.078%
Pharmena S.A.	33.78 Million PLN	175.506%
Poltreg S.A.	-11.65 Million PLN	-118.765%
Pure Biologics Spólka Akcyjna	-26.07 Million PLN	2.19%
Ryvu Therapeutics S.A.	-81.04 Million PLN	68.528%
Synthaverse S.A.	15.34 Million PLN	266.205%
Urteste S.A.	-5.73 Million PLN	-345.05%